The effect of growth hormone replacement therapy on craniopharyngioma recurrence: a systematic review and meta-analysis
Pooled result · RecurrenceResult — go to the resultOdds ratio 0.56 95% CI 0.41–0.77Authors' conclusion
The meta-analysis shows that GHRT does not increase the risk of recurrence in CP, even when initiated within 12 months postoperatively. GHRT should be considered an essential treatment for CP patients with GHD.
Study context
- Population
- Pediatric and adult patients with craniopharyngioma12 studies
- Comparison
- Growth hormone replacement therapy (GHRT) vs no GHRT
- Outcome
- CP recurrence
Methodological detailsPRISMA 2020
- PRISMA 2020
Pooled result
Recurrence
Odds ratio
0.56
95% CI 0.41–0.77
GHRTvs non-GHRT
OR 0.56 (95% CI 0.41–0.77)
As reported in the abstract
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| Recurrence, GHRT initiated within 12 months after CP treatment | 0.32 (0.16–0.62) | |
| 0.10.31310Odds ratio (log scale) |
Recurrence, subgroup follow-up >5 years
- GHRT had a more significant effect with follow-up >5 years
Sensitivity analyses and publication bias
- Results were robust
Original publication
The effect of growth hormone replacement therapy on craniopharyngioma recurrence: a systematic review and meta-analysis. Pituitary. Published 5 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →